Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma is a research paper published in Clinical Genitourinary Cancer (2021). On theSindex it has a DataRank of 0.848. It has been cited 20 times, with 17 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.457
From this paper's citation signal
Citation Network Contribution
0.391
From 14 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 17 citers.
Pfizer
Grant: B9991002
Pfizer
Grant: B9991003
Bristol-Myers Squibb
Exelixis
Genentech
American Society of Clinical Oncology
Merck KGaA
National Institutes of Health
Roche
F. Hoffmann-La Roche
National Cancer Institute
Alexion Pharmaceuticals
Merck
National Comprehensive Cancer Network
Novartis
Eli Lilly and Company
Bayer Fund
GlaxoSmithKline
Shionogi
Takeda Pharmaceuticals U.S.A.
U.S. Department of Defense
AstraZeneca
FWCI
1.83
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals